In pregnant women with type 1 diabetes, degludec was found to be non-inferior to detemir (The Lancet Diabetes & Endocrinology)
Diabetes News
Tag: Type 1 Diabetes
Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
Serum insulin rapidly increased post-dose and returned to baseline by 120 min. The data suggests the PK of TI in youth with T1D ages 8–17 years was similar to that seen in previous adult studies (Diabetes Therapy)
Cardiovascular outcomes in type 1 and type 2 diabetes
As illustrated by the literature discussed above, comparison between individuals with type 1 and type 2 diabetes with respect to risk of CVD is fraught with difficulties and highly dependent on other concomitant factors, some of which are modifiable and others not (Diabetologia)
Importance of beta cell mass for glycaemic control in people with type 1 diabetes
Our data show higher beta cell mass in people with type 1 diabetes and LGV than in those with HGV, independent of beta cell function (Diabetologia)
Attendance at pre-pregnancy care clinics for women with type 1 diabetes: a scoping review
This review highlights the ongoing problem of poor-attendance at PPC and identifies key barriers to be addressed when developing and implementing PPC programs for women with type 1 diabetes (Diabetic Medicine)
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
A personalized alternative to annual screening in type 1 diabetes can substantially reduce both the time with undetected kidney disease and the frequency of urine testing (Diabetes Care)
Pancreatic islet transplantation in type 1 diabetes: Current state and future perspectives
Based on current data, islet transplantation successfully reduces severe hypoglycemia and insulin requirement. However, graft survival is still not good enough, which leads to a low rate of insulin independence and an unsatisfactory long-term glycemic control (Journal of Diabetes Investigation)
Clinical and Safety Outcomes with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
GLP-1RA and SGLT2i use in T1DM is associated with clinically relevant benefits. DKA remains a clinical concern with SGLT2i use, requiring careful patient selection and monitoring, with the risk to benefit ratio of treatment evaluated at an individual level (Journal of Clinical Endocrinology & Metabolism)
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study
In people with type 1 diabetes using multiple daily injections of insulin plus isCGM and with HbA1c of at least 8%, the use of AHCL confers benefits in terms of glycaemic control beyond those that can be achieved with multiple daily injections of insulin plus isCGM. These data support wider access to AHCL in people with type 1 diabetes not at target glucose levels (The Lancet Diabetes & Endocrinology)
Open-source Closed-Loop System Is Effective for Type 1 Diabetes
The study adds to a growing body of evidence that AID systems, including commercial AIDs, are “remarkably consistent” in keeping blood glucose in target range, according to an editorial that accompanied the findings in the New England Journal of Medicine (JAMA)
Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes
Among participants with type 1 diabetes and high glycated hemoglobin levels, the use of intermittently scanned continuous glucose monitoring with optional alarms for high and low blood glucose levels resulted in significantly lower glycated hemoglobin levels than levels monitored by fingerstick testing (NEJM)
Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry
In recipients with type 1 diabetes complicated by SHEs, islet transplantation meeting 4CFF protected 95% from SHEs at 5 years after the last islet infusion and exerted a large and significant benefit on glycaemic control, with an acceptable safety profile for this subgroup of type 1 diabetes (Diabetologia)
The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study
A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes (Diabetes Technology and Therapeutics)
Real-world glycaemic outcomes in adult persons with type 1 diabetes using a real-time continuous glucose monitor compared to an intermittently scanned glucose monitor
A retrospective observational study from the Canadian LMC diabetes registry (REAL-CGM-T1D) (Diabetic Medicine)
Open-Source Automated Insulin Delivery in Type 1 Diabetes
In children and adults with type 1 diabetes, the use of an open-source AID system resulted in a significantly higher percentage of time in the target glucose range than the use of a sensor-augmented insulin pump at 24 weeks (NEJM)
Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes
In youths with new-onset type 1 diabetes, intensive glucose control for 24 months did not appear to prevent the decline in residual C-peptide secretion (NEJM)
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study
In people with type 1 diabetes using multiple daily injections of insulin plus isCGM and with HbA1c of at least 8%, the use of AHCL confers benefits in terms of glycaemic control beyond those that can be achieved with multiple daily injections of insulin plus isCGM. These data support wider access to AHCL in people with type 1 diabetes not at target glucose levels (The Lancet Diabetes & Endocrinology)
The Gut Microbiome Composition Is Altered in Long-standing Type 1 Diabetes and Associates With Glycemic Control and Disease-Related Complications
Our data show that the gut microbiome is altered in people with (long-standing) type 1 diabetes and is associated with glycemic control and diabetes-related complications. As a result of the cross-sectional design, the causality of these relationships remains to be determined (Diabetes Care)
Impact of glycaemic technologies on quality of life and related outcomes in adults with type 1 diabetes: a narrative review
PROs are usually assessed as secondary outcomes in glycaemic technology studies. Hypoglycaemia-specific and diabetes-specific, but not generic, PROs show benefits of glycaemic technologies, and deserve a more central role in future studies as well as routine clinical care (Diabetic Medicine)
Precision medicine in type 1 diabetes
In this review, we discuss how these personalised approaches have improved diabetes care and how improved understanding of pathogenesis and human biology might inform precision medicine in the future (Diabetologia)
- 1
- 2
- 3
- …
- 23
- Next Page »